Latest stories on IKT
Inhibikase Therapeutics GAAP EPS of -$0.10 beats by $0.01
Seeking Alpha58 · neutralearnings
Inhibikase Therapeutics, Inc. (IKT) files 8-K: Items 2.02, 9.01
SEC 8-K50 · neutralgeneral
Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
GlobeNewswire52 · neutralearnings
Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
StockTitan52 · neutralearnings
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
GlobeNewswire53 · neutralproduct/pr
Inhibikase Appoints Scott Wasserman to Board of Directors
TipRanks52 · neutralgeneral
Inhibikase Therapeutics, Inc. (IKT) files 8-K
SEC 8-K50 · neutralgeneral
Inhibikase Therapeutics appoints Kailera CMO Scott Wasserman to board
The Fly56 · neutralgeneral
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
StockTitan53 · neutralgeneral
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
GlobeNewswire53 · neutralgeneral
Inhibikase Therapeutics initiated with a Neutral at Chardan
The Fly50 · neutralanalyst
Chardan initiates Inhibikase Therapeutics stock with neutral rating
Investing.com Analyst Ratings50 · neutralanalyst
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Inhibikase Therapeutics, Inc. (IKT) files 8-K
SEC 8-K50 · neutralgeneral
Inhibikase Therapeutics, Inc. (IKT) files 8-K
SEC 8-K50 · neutralgeneral
Inhibikase Therapeutics GAAP EPS of -$0.11 in-line
Seeking Alpha52 · neutralearnings
Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c)
The Fly42 · neutralearnings
Inhibikase Therapeutics, Inc. (IKT) files 8-K
SEC 8-K50 · neutralgeneral
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
GlobeNewswire50 · neutralgeneral
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
StockTitan50 · neutralgeneral
Inhibikase Therapeutics, Inc. (IKT) files 8-K
SEC 8-K50 · neutralgeneral
Inhibikase Therapeutics, Inc. (IKT) files 8-K
SEC 8-K50 · neutralgeneral
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
Business Insider67 · bullishproduct/pr
Inhibikase Lands $50 Million ATM Financing: Sufficient Cash Runway Boosts Phase 3 PAH Trial Prospects
July 14, 2026
MarketChameleon48 · neutralgeneral